( August 4, 2026, 3:07 PM EDT) -- NEW YORK — A New York federal judge ruled that Novo Nordisk A/S and Novo Nordisk Inc. failed to plausibly allege that a company falsely advertised compounded semaglutide products as equivalent to Novo Nordisk’s FDA-approved medications, granting a motion to dismiss the Lanham Act claims but allowing leave to amend the complaint....